Implementation of mechanism of action biology-driven early drug development for children with cancer
详细信息 查看全文
- 作者：Andrew D.J. Pearsona ; 1 ; andy1pearson@btinternet.com" class="auth_mail" title="E-mail the corresponding author ; Ralf Heroldb ; Raphaë ; l Rousseauc ; Chris Coplandd ; Brigid Bradley-Garelike ; Debbie Binnerf ; Renaud Capdevilleg ; Hubert Caronh ; i ; Jacqueline Carleerj ; Louis Cheslerk ; Birgit Geoergerl ; Pamela Kearnsm ; Lynley V. Marshalla ; n ; Stefan M. Pfistero ; Gudrun Schleiermacherp ; Jeffrey Skolnikq ; Cesare Spadonir ; Jaroslav Sterbas ; t ; Hendrick van den Bergb ; Martina Uttenreuther-Fischeru ; Olaf Wittv ; Koen Norgaw ; Gilles Vassalx ; on behalf of Members of Working Group 1 of the Paediatric Platform of ACCELERATE2 ; B. Georgery ; R. Iannonez ; R. Jakackiz ; M. Russoaa
- 关键词：Paediatric oncology ; Mechanism of action ; Targeted cancer drug development
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：62
- 期：Complete
- 页码：124-131
- 全文大小：408 K
文摘
- •
The need for new drugs for children with cancer is greater than ever.
- •
Paediatric drug development still largely centres on adult conditions.
- •
A mechanism of action model of drug development is proposed by ACCELERATE.
- •
An aggregated paediatric tumour biological database matches the drug pipeline.
- •
This new paradigm allows early evaluation of new drugs in children and teenagers.